Justin Watts - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Justin Watts

Showing results (31-40 of 36) with videos related to

Pageof 4

Sort By:

You have reached the last page of results.This site can display upto 36 results.

Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.

Cancer Cell|June 13, 2018

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal HematopoiesisSarah M Greenblatt, Na Man, Pierre-Jacques Hamard, et al.

Blood Neoplasia|June 2, 2025

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.

Haematologica|February 26, 2026

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.

Blood|January 10, 2023

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signaturesBenjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelCurtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.

Pageof 4

Search research articles

Showing results (31-40 of 36) with videos related to

Sort By:

Pageof 4

You have reached the last page of results.This site can display upto 36 results.

Proceedings of the National Academy of Sciences of the United States of America|August 9, 2017

Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignanciesStephen E Kurtz, Christopher A Eide, Andy Kaempf, et al.

Cancer Cell|June 13, 2018

CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal HematopoiesisSarah M Greenblatt, Na Man, Pierre-Jacques Hamard, et al.

Blood Neoplasia|June 2, 2025

Venetoclax and hypomethylating agents in octogenarians and nonagenarians with acute myeloid leukemiaEllen Madarang, Jillian Lykon, Wei Zhao, et al.

Haematologica|February 26, 2026

Venetoclax and azacitidine for younger acute myeloid leukemia patients independent of fitness for intensive chemotherapyJustin Watts, Ellen Madarang, Diana Abbott, et al.

Blood|January 10, 2023

Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signaturesBenjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026

Risk Prognostication After Hypomethylating Agents Combined With Venetoclax in AML: The PRISM Risk ModelCurtis A Lachowiez, Joshua F Zeidner, Jad Othman, et al.

Pageof 4